Ovarian Cancer Vaccine
Ovarian Cancer
Key Facts
About Anixa Biosciences
Anixa Biosciences is a clinical-stage biotech focused on transforming oncology through its innovative 'retired protein' antigen platform, which aims to deliver tumor-specific immunotherapies with improved safety profiles. The company's two core technologies are a novel CER-T (Chimeric Endocrine Receptor T-cell) therapy for ovarian cancer and a vaccine platform targeting triple-negative breast cancer (TNBC) and ovarian cancer for both treatment and prevention. Recent milestones include advancing its breast cancer vaccine toward Phase 2 and presenting early clinical data for its ovarian cancer CAR-T therapy. Anixa's strategy targets significant unmet needs in solid tumors by aiming to overcome the on-target, off-tumor toxicity that has limited broader application of current immunotherapies.
View full company profileOther Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |